Currently 3560 jobs
REGULATED INFORMATION
GHENT, Belgium, 9 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received notifications of shareholdings from FMR LLC on 6 and 7 March 2018.
On 6 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has downward crossed the 5% threshold of total voting rights of Ablynx since 1 March 2018.
On 7 March 2018, FMR LLC (taking into account the holdings of its subsidiary undertakings) has notified Ablynx that it has first downward crossed and then upward crossed the 3% threshold of voting rights (excluding the ones held through financial instruments) on respectively 5 and 6 March 2018.
FMR LLC now holds a total of 2,780,276 voting securities of Ablynx since 6 March 2018, representing 3.70% of the current 75,073,886 outstanding voting rights of Ablynx (versus 5.92% notified previously on 8 February 2018).
The latest notification contains the following information:
| Name of select subsidiaries of FMR LLC | % of voting rights | % of voting rights held through financial instruments* | Total of both |
| FMR LLC Fidelity Management & Research Company FMR Co., Inc. | 1.69% | 0.28% | 1.97% |
| FMR LLC FIAM Holdings Corp. Fidelity Institutional Asset Management Trust Company | 1.00% | 1.00% | |
| FMR LLC FIAM Holdings Corp. FIAM LLC | 0.74% | 0.74% | |
| TOTAL | 3.43% | 0.28% | 3.70% |
* Type of financial instrument: "Right of Recall"
More information is available in the transparency notifications. A full version of the transparency notifications is available on Ablynx website, under the section Investors.
The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank, Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/314ed48d-abc9-4013-90f6-23b70b56d757
GlobeNewswireLast updated on: 09/03/2018
Pharmiweb.com RSS Feeds 